We designed in vitro macrophage migration and phagocytosis assays to evaluate the efficacy of anti-CD47 mAb alone or with bevacizumab as a therapeutic in gastric cancer, especially for preventing early seeding events. This evidence concerns the gene CD47 and gastric cancer.